Fig. 1: Flow diagram of the patients included in this study.

*Patients who developed destructive thyroiditis and/or hypothyroidism induced by anti-PD-1 antibodies. Pem pembrolizumab, Niv nivolumab, US ultrasonography, AG adenomatous goitre, TPOAb anti-thyroid peroxidase antibodies, TgAb anti-thyroglobulin antibodies.